|
Security
Type
|
Security
Class
Title
|
Fee
Calculation
Rule
|
Amount
Registered(1)
|
Proposed
Maximum
Offering
Price
Per Unit
|
Maximum
Aggregate
Offering Price
|
Fee Rate
|
Amount of
Registration
Fee
|
|||||||||||||||
|
Equity
|
Common Stock, par value
$0.00033
|
Rule 457(c) and Rule
457(h)
|
1,000,000
|
(2)
|
$
|
4.7175
|
(3)
|
$
|
4,717,500.00
|
(3)
|
$
|
0.00014760
|
$
|
696.30
|
||||||||
|
Total Offering Amounts
|
$
|
4,717,500.00
|
$
|
696.30
|
||||||||||||||||||
|
Total Fee Offsets(4)
|
-
|
|||||||||||||||||||||
|
Net Fee Due
|
$
|
696.30
|
||||||||||||||||||||
| (1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 shall cover any additional shares of common stock,
$0.00033 par value per share (“Common Stock”) of the Registrant that become issuable under the PDS Biotechnology Corporation 2019 Inducement Plan, as amended (the “Inducement Plan”) by reason of any stock dividend, stock split,
recapitalization, or other similar transaction effected without the Registrant’s receipt of consideration which results in an increase in the number of the outstanding shares of Common Stock.
|
| (2) |
Represents an increase in the number of shares of Common Stock reserved for issuance under the Inducement Plan, pursuant to an amendment to the Inducement Plan effective as of January 22,
2024.
|
| (3) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high
($4.87) and low ($4.565) prices of the Registrant’s Common Stock as reported on Nasdaq on March 22, 2024.
|
| (4) |
The Registrant does not have any fee offsets.
|